Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan.

Mood Disorders Center, Portland VA Medical Center, Portland, OR 97239, USA.
Pharmacology [?] Therapeutics (Impact Factor: 7.75). 04/2006; 109(3):325-38. DOI: 10.1016/j.pharmthera.2005.06.004
Source: PubMed

ABSTRACT This paper reviews the preclinical and clinical evidence regarding the use of the dietary supplement 5-hydroxytryptophan (5-HTP) for the treatment of depression. In the absence of supplementation with exogenous 5-HTP, the amount of endogenous 5-HTP available for serotonin synthesis depends on the availability of tryptophan and on the activity of various enzymes, especially tryptophan hydroxylase, indoleamine 2,3-dioxygenase, and tryptophan 2,3-dioxygenase (TDO). Factors affecting each of these are reviewed. The amount of 5-HTP reaching the central nervous system (CNS) is affected by the extent to which 5-HTP is converted to serotonin in the periphery. This conversion is controlled by the enzyme amino acid decarboxylase, which, in the periphery, can be blocked by peripheral decarboxylase inhibitors (PDIs) such as carbidopa. Preclinical and clinical evidence for the efficacy of 5-HTP for depression is reviewed, with emphasis on double-blind, placebo-controlled (DB-PC) trials. Safety issues with 5-HTP are also reviewed, with emphasis on eosinophilia myalgia syndrome (EMS) and serotonin syndrome.


Available from: Jennifer M Loftis, May 30, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The study consisted of experiments using edible mushroom species: Agaricus bisporus, Boletus badius and Cantharellus cibarius. As far as we know, there is no information about the release of indole compounds from mushrooms in the human body. The rate of the release of indole compounds was determined by HPLC method and on this basis it was possible to ascertain new important information about the safety and benefits of adding edible mushrooms to the diet. The experiments to verify the release of indole compounds in the artificial gastric juice were performed using the fruiting bodies of the studied species, and the corresponding mycelium obtained by in vitro culture. The highest levels of indole compounds concentration after extraction for 15, 30, 60 and 90 min were observed for in vitro cultures of the examined mushrooms. These concentrations ranged from 0.01 to 109 mg/100 g dry weight for serotonin and 5-OH-l-tryptophan, respectively. The dominant indole compound was 5-OH-l-tryptophan both in extracts derived from fruiting bodies and in mycelium collected from in vitro culture with the addition of zinc hydroaspartate (28–109 mg/100 g dry weight). Generally, the lower levels of the released compounds were found in extracts from the fruiting bodies.
    Lebensmittel-Wissenschaft und-Technologie 06/2015; 106(1). DOI:10.1016/j.lwt.2015.01.037 · 2.47 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Serotonergic agents usually attenuate light-induced phase shifts in nocturnal species. L-5-Hydroytrytptophan (5-HTP) is a non-specific serotonergic agonist and the natural precursor of serotonin. We investigated the ability of 5-HTP to potentiate or attenuate light-induced phase shifts using a comparatively lower intensity of light (∼70 lux). Mice free-running in DD were given either light exposure at circadian times (CTs) 15 and 21 with saline (light-exposed control) or 50 mg/kg of 5-HTP (Himedia) at 0.5 circadian h prior to light exposure. L-5-Hydroytrytptophan potentiated the phase advance of the rhythm caused by light at CT 21; however, 5-HTP fails to significantly attenuate/potentiate phase delays. Total activity increased during phase advance potentiation, compared to control, indicating that this phenomenon may possibly be at least partially behavioral arousal-dependent. These preliminary findings are interesting and unexpected; further experimentation is necessary, and the results indicate possible scope for use of 5-HTP in chronotherapy.
    Biological Rhythm Research 08/2013; 44(4):569-575. DOI:10.1080/09291016.2012.730889 · 1.22 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The brain serotonin level is decreased in individuals with autism. Buspirone is a 5-HT(1A) receptor agonist with antiaggressive effects increasing prosocial behaviors. We conducted an 8-week randomized double-blind placebo-controlled clinical trial. Participants included 40 outpatient children and adolescents with autism. The patients took buspirone plus risperidone or risperidone plus placebo during 8 weeks. The patients were assessed at baseline, week 4, and week 8 using the Aberrant Behavior Checklist-Community Rating Scale. Eighteen patients in the placebo group and 16 patients in the buspirone group completed this trial. The mean dose of buspirone was 6.7 (SD 2.7) mg/day. Irritability subscale score significantly decreased during this trial in both groups (buspirone group: declined from 25.7 [SD 5.7] to 16.3 [SD 8.5]; placebo group: declined from 24.7 [SD 7.6] to 18.2 [SD 7.7]). The Cohen d effect size was .45. Thirteen (81.2%) of 16 patients in the buspirone group and 7 (38.9%) of 18 patients in the placebo group indicated ≥30% decline in irritability score. The relative risk for treatment was 2.1. There were no serious adverse effects. The most common adverse effects in the buspirone group were increased appetite, drowsiness, and fatigue. This clinical trial supports that low dose buspirone plus risperidone is more effective than risperidone plus placebo for treating irritability in individuals with autism. Copyright © 2014 Elsevier Inc. All rights reserved.
    Pediatric Neurology 10/2014; 52(1). DOI:10.1016/j.pediatrneurol.2014.09.017 · 1.50 Impact Factor